目的探討胃癌患者外周血淋巴細(xì)胞（PBL）CD44變異體5（CD44v5）含量和瘤組織CD44v5表達(dá)情況，及其對胃癌轉(zhuǎn)移的診斷和進(jìn)展評價的意義。方法應(yīng)用流式細(xì)胞儀（FCM）檢測31例胃癌患者術(shù)前PBL CD44v5含量并與正常對照組相比較，同時采用免疫組化SABC法檢測33例胃癌組織CD44v5表達(dá)情況。結(jié)果胃癌患者術(shù)前PBL CD44v5含量較正常對照組明顯增高（P＜0.01）。有轉(zhuǎn)移的胃癌患者PBL CD44v5含量明顯高于無轉(zhuǎn)移者（P＜0.01）。術(shù)前PBL CD44v5含量與腫瘤大小、浸潤深度、淋巴結(jié)轉(zhuǎn)移及病理分期呈顯著的正相關(guān)（r=0.486，P＜0.05）。正常胃粘膜無CD44v5表達(dá)，胃癌組織CD44v5表達(dá)陽性率為69.7%，其表達(dá)與腫瘤浸潤深度和淋巴結(jié)轉(zhuǎn)移存在顯著相關(guān)性。胃癌原發(fā)灶CD44v5表達(dá)陽性者其淋巴結(jié)轉(zhuǎn)移陽性率顯著高于陰性者。結(jié)論CD44v5有望作為監(jiān)測胃癌轉(zhuǎn)移的生物學(xué)指標(biāo)。應(yīng)用FCM定量檢測胃癌患者術(shù)前外周血CD44v5含量，對胃癌轉(zhuǎn)移的診斷和進(jìn)展的評價可能具有重要的臨床意義。
引用本文： 陳國玉,趙慶洪,袁景倫,武正炎,夏建國,章希煒. 胃癌患者外周血及瘤體CD44v5的表達(dá)與轉(zhuǎn)移相關(guān)性研究. 中國普外基礎(chǔ)與臨床雜志, 2002, 9(3): 148-150. doi: 復(fù)制
| 1. | Saito H, Tsujiatani S, Katano K, et al. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma [J]. Cancer， 1998; 83（6）∶1094. |
| 2. | Naot D, Sionov RV, Ish SD, et al. CD44: structure, function, and association with the malignant process [J]. Adv Cancer Res， 1997； 71(2)∶241. |
| 3. | Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells [J]. Cell， 1991； 65（1）∶13. |
| 4. | Harn HJ, Ho LI，Chang JY, et al. Differential expression of the human metastasis adhesion molecule CD44v in normal and carcinomatous stomach mucosa of Chinese subjects [J]. Cancer， 1995； 75（5）∶1065. |
| 5. | Muller W, Scheiders A, Heider KH,et al.Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer [J]. J Path， 1997; 183（2）∶222. |
| 6. | Arch R，Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasisinducing splice variant of CD44 [J]. Science， 1992； 257（5070）∶682. |
- 1. Saito H, Tsujiatani S, Katano K, et al. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma [J]. Cancer， 1998; 83（6）∶1094.
- 2. Naot D, Sionov RV, Ish SD, et al. CD44: structure, function, and association with the malignant process [J]. Adv Cancer Res， 1997； 71(2)∶241.
- 3. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells [J]. Cell， 1991； 65（1）∶13.
- 4. Harn HJ, Ho LI，Chang JY, et al. Differential expression of the human metastasis adhesion molecule CD44v in normal and carcinomatous stomach mucosa of Chinese subjects [J]. Cancer， 1995； 75（5）∶1065.
- 5. Muller W, Scheiders A, Heider KH,et al.Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer [J]. J Path， 1997; 183（2）∶222.
- 6. Arch R，Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasisinducing splice variant of CD44 [J]. Science， 1992； 257（5070）∶682.